Genetic susceptibility for Alzheimer disease neuritic plaque pathology

JAMA Neurology

Volumn 70, Issue 9, 2013, Pages 1150-1157

  Shulman, Joshua M ^a,b   Chen, Kewei ^c,d   Keenan, Brendan T ^e,f,g   Chibnik, Lori B ^e,f,g   Fleisher, Adam ^c,h   Thiyyagura, Pradeep ^c,d   Roontiva, Auttawut ^c,d   McCabe, Cristin ^e,f,g   Patsopoulos, Nikolaos A ^e,f,g   Corneveaux, Jason J ⁱ   Yu, Lei ^j   Huentelman, Matthew J ⁱ   Evans, Denis A ^k,l   Schneider, Julie A ^j,l   Reiman, Eric M ^c,d,i   De Jager, Philip L ^e,f,g   Bennett, David A ^j,l  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^j RUSH UNIVERSITY MEDICAL CENTER   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ABCA7 GENE; ALZHEIMER DISEASE; APOE GENE; APP GENE; ARTICLE; ATP5J GENE; AUTOPSY; COHORT ANALYSIS; CONTROLLED STUDY; CR1 GENE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HLA DQA2 GENE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KCNIP4 GENE; MAJOR CLINICAL STUDY; NMNAT3 GENE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 1 GENE; PSEN1 GENE; PSEN2 GENE; RISK ASSESSMENT; SENILE PLAQUE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84883748375     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.2815     Document Type: Article

References (38)

1. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin. 2007;25(3):611-667; v.
2. Jónsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488(7409):96-99.
3. Hooli BV, Mohapatra G, Mattheisen M, et al. Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology. 2012;78(16):1250-1257.
4. Nowotny P, Simcock X, Bertelsen S, et al. Association studies testing for risk for late-onset Alzheimer's disease with common variants in the beta-amyloid precursor protein (APP). Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):469-474. (Pubitemid 46983157)
5. Guyant-Maréchal L, Rovelet-Lecrux A, Goumidi L, et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology. 2007;68(9):684-687. (Pubitemid 46667816)
6. Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B. Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol. 2002;59(11):1793-1799. (Pubitemid 35340491)
7. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3(89):89ra57.
8. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41(10):1088-1093.
9. Hollingworth P, Harold D, Sims R, et al Alzheimer's Disease Neuroimaging Initiative; CHARGE Consortium; EADI1 Consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-435.
10. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-441.
11. Lambert JC, Heath S, Even G, et al European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094- 1099.
12. Seshadri S, Fitzpatrick AL, Ikram MA, et al CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832-1840.
13. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41(2):193-202. (Pubitemid 38125181)
14. Chibnik LB, Shulman JM, Leurgans SE, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol. 2011;69(3):560-569.
15. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76(9):1194-1199. (Pubitemid 41208366)
16. Wyss-Coray T, Yan F, Lin AH-T, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A. 2002;99(16):10837-10842.
17. Treusch S, Hamamichi S, Goodman JL, et al. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science. 2011;334(6060):1241-1245.
18. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406-413. (Pubitemid 350105954)
19. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-208.
20. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
21. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665-680. (Pubitemid 351294719)
22. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106(16):6820-6825.
23. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
24. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.
25. Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72(17):1495-1503.
26. McQueen MB, Bertram L, Lange C, et al. Exploring candidate gene associations with neuropsychological performance. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(8):987-991. (Pubitemid 350207770)
27. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res. 2012;9(6):628-645.
28. Bennett DAD, Schneider JAJ, Buchman ASA, Barnes LLL, Boyle PAP, Wilson RSR. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res. 2012;9(6):646-663.
29. Keenan BT, Shulman JM, Chibnik LB, et al Alzheimer's Disease Neuroimaging Initiative. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline. Hum Mol Genet. 2012;21(10):2377-2388.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
31. National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(4)(suppl):S1-S2.
32. Massone S, Vassallo I, Castelnuovo M, et al. RNA polymerase III drives alternative splicing of the potassium channel-interacting protein contributing to brain complexity and neurodegeneration. J Cell Biol. 2011;193(5):851-866.
33. Liu F, Arias-Vásquez A, Sleegers K, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007;81(1):17-31. (Pubitemid 47001153)
34. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24-26. (Pubitemid 43011878)
35. Morohashi Y, Hatano N, Ohya S, et al. Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. J Biol Chem. 2002;277(17):14965-14975. (Pubitemid 34952571)
36. Hoozemans JJM, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des. 2008;14(14):1419-1427. (Pubitemid 351982549)
37. Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature. 2008;452(7189):887-891. (Pubitemid 351550857)
38. Arnold SE, Louneva N, Cao K, et al. Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol Aging. 2013;34(1):157-168.